enzastaurin

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Neoplasms

Conditions

Neoplasms, Cancer

Trial Timeline

Mar 1, 2006 → Jul 1, 2009

NCT ID

NCT00309140

About enzastaurin

enzastaurin is a phase 2 stage product being developed by Eli Lilly for Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00309140. Target conditions include Neoplasms, Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Neoplasms were approved

Approved (20) Terminated (2) Active (0)

✅LenvatinibEisaiApproved

✅Eribulin mesylateEisaiApproved

✅Eribulin MesylateEisaiApproved

✅Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) + FulvestrantEli LillyApproved

✅Chlorhydrate de RopivacaineAstraZenecaApproved

✅Sitagliptin + placeboMerckApproved

✅Palonosetron and DexamethasoneMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01432951	Phase 1	Completed	Nov 1, 2011	Jan 5, 2018	Solid Tumor
NCT00744991	Phase 2	Completed	Sep 1, 2008	Feb 1, 2010	Cutaneous T-Cell Lymphoma
NCT00718419	Phase 2	Completed	Jul 1, 2008	Aug 1, 2012	Waldenstrom's Macroglobulinemia
NCT00542919	Phase 2	Completed	Nov 1, 2007	Feb 27, 2018	T-Cell Lymphoma
NCT00475644	Phase 2	Completed	May 1, 2007	Dec 1, 2014	Lymphoma, Follicular
NCT00452257	Phase 1	Completed	May 1, 2007	Sep 1, 2008	Leukemia, Lymphocytic
NCT00420381	Phase 2	Completed	Jan 1, 2007	Dec 1, 2014	Ovarian Cancer
NCT00428714	Phase 2	Completed	Jan 1, 2007	Jan 1, 2011	Prostate Cancer
NCT00309140	Phase 2	Completed	Mar 1, 2006	Jul 1, 2009	Neoplasms
NCT00088205	Phase 2	Completed	Mar 1, 2004	May 1, 2008	Mantle-Cell Lymphoma
NCT00190723	Phase 2	Completed	Oct 1, 2002	Dec 1, 2006	Malignant Glioma

Competing Products

20 competing products in Neoplasms

See all competitors

Product	Company	Stage	Hype Score
ADC-1013	Alligator Bioscience AB	Phase 1	19
AB0024	Gilead Sciences	Phase 1	29
TTI-237	Pfizer	Phase 1	21
852A	Pfizer	Phase 1	29
Pemetrexed	Eli Lilly	Phase 2	35
IMC-3C5	Eli Lilly	Phase 1	29
LY3295668	Eli Lilly	Phase 1/2	32
Galunisertib + Gemcitabine + Placebo	Eli Lilly	Phase 1/2	32
Fulvestrant + Abemaciclib	Eli Lilly	Phase 2	39
Abemaciclib + Fulvestrant + Placebo	Eli Lilly	Phase 3	44
LY2784544	Eli Lilly	Phase 1	29
Abemaciclib + Darolutamide + LHRH agonist/antagonist	Eli Lilly	Phase 1	29
Gemcitabine + liposomal doxorubicin	Eli Lilly	Phase 3	40
120 mg LY2784544	Eli Lilly	Phase 2	39
LY4337713	Eli Lilly	Phase 1	36
pemetrexed + cisplatin	Eli Lilly	Phase 1/2	32
LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + Fulvestrant	Eli Lilly	Phase 3	47
VIP152 (BAY 1251152) + VIP152 (BAY 1251152) 30 mg + Keytruda + VIP152 (BAY 1251152) 15 mg	Vincerx Pharma	Phase 1	19
VIP236 (Q3W) + VIP236 (Q2W)	Vincerx Pharma	Phase 1	19
GEMZAR + ALIMTA	Eli Lilly	Phase 3	40